Sight Restored After 55 Years


Surgery has restored sight in the eye of a man who for 55 years had a detached retina that left him blind in his right eye after it was hit by a stone when he was 8 years old. Thought to be the first time sight has been restored after such a long period of blindness following retinal detachment, doctors are hopeful that the result will help restore sight in other patients, for example in combination with stem cell treatment to regrow cells lost through retinal disease.

A report, describing how doctors at The New York Eye and Ear Infirmary (NYEEI) managed to restore functional vision in a patient's eye after 55 years of blindness following a childhood accident, is about to be published in the open access Journal of Medical Case Reports.

First author Dr Olusola Olawoye, a recipient of a 2009 International Council of Ophthalmology Fellowship to train at the NYEEI, told the press that:

"To the best of our knowledge this is the first report of visual recovery in a patient with long-standing traumatic retinal detachment."

The retina is a thin layer of light-sensitive cells at the back of the eye. It rarely becomes detached, but when it does, most commonly as a result of head injury, age or diabetes, it pulls away from its blood supply, leaving the retinal cells without oxygen and nutrients, and they eventually die off.

If the retina remains detached for a long time, because the cells have died, it is often impossible to restore sight, even if physically, the retina is reattached successfully.

Although he had surgery when he was 23 to remove a cataract, and that temporarily restored some ability to see light, the unnanmed 63-year-old man in this case was completely blind in his right eye when he went to the NYEEI complaining of pain in his eye.

When they examined him, doctors found he had total hyphema (where blood pools in the front part of the eye), neovascular glaucoma (a secondary type of glaucoma that results from the growth of new blood vessels in areas where they do not belong), high intraocular pressure (high pressure in the fluid inside the eye), and a detached retina.

The first thing they did was to treat the high pressure in the eye to relieve the pain.

Once the eye pressure was stable, the doctors then treated the neovascular glaucoma with monoclonal antibody therapy. To their complete surprise, the patient started seeing some light in that eye.

After this encouraging result they decided to try surgery to reattach the retina. The operation was so successful that the patient was able to see well enough to count fingers from five meters away.
Although he needed another operation 12 months later, when the scars inside his eye were forcing parts of the retina to detach again, this was also successful.

Olawoye said:

"This is not only a great result for our patient but has implications for restoring eyesight in other patients, especially in the context of stem cell research into retinal progenitor cells which may be able to be transplanted into diseased retinas to restore vision."

While pleased with the results for this patient, other experts have been more cautious about the implications for others.

BBC News reports that surgeons say the operation was successful because of the low "height" of the retinal detachment (a measure of the distance between the detached outer surface of the light-sensitive part of the retina and the underlying pigment layer).

Lyndon da Cruz, a consultant opthalmic surgeon at Moorfields Eye Hospital in London, whose research interest includes cell transplantation for retinal dystrophy, reminded the UK's Daily Express newspaper that the patient in this case only experienced slight improvement in vision.

You can reattach the retina after 55 years, but sight doesn't just "bounce back to normal", he said, adding:

"This is why we need stem cells to support the retinal cells after reattachment."

"Visual recovery in a patient with total hyphema, neovascular glaucoma, long-standing retinal detachment and no light perception vision: a case report."
Olusola Olawoye, Christopher C Teng, Uri Shabto, Jeffrey M Liebmann, Francis A L'Esperance and Robert Ritch.
Journal of Medical Case Reports (in press)

Sources: BioMed Central via Eurekalert!, Daily Express, BBC.

E. Coli Bacteria More Likely To Develop Resistance After Exposure To Low Levels Of Antibiotics Reports A Study In Microbial Drug Resistance


E. coli bacteria exposed to three common antibiotics were more likely to develop antibiotic resistance following low-level antibiotic exposure than after exposure to high concentrations that would kill the bacteria or inhibit their growth, according to a timely article in Microbial Drug Resistance, a peer-reviewed journal published by Mary Ann Liebert, Inc.

E. coli bacteria in food and water supplies have been responsible for disease outbreaks and deaths around the world in recent years. The current outbreak in Europe has sickened thousands of individuals and caused multiple deaths and life-threatening complications in hundreds of persons infected with a new strain of E. coli.

Bacterial resistance to commonly prescribed antibiotics is an enormous and growing problem, largely due to misuse of antibiotics to treat non-bacterial infections and environmental exposure of the bacteria to low levels of antibiotics used, for example, in agriculture. In the article "De Novo Acquisition of Resistance to Three Antibiotics by Escherichia coli," the authors studied the mechanisms by which E. coli acquire resistance to three common antibiotics: amoxicillin, tetracycline, and enrofloxacin. Depending on the antibiotic and the level of exposure, different mechanisms may come into play. The authors report that exposure to antibiotics at relatively low levels--below those needed to inhibit growth of the bacteria--are more likely to result in the development of antibiotic resistance. "Exposure to low levels of antibiotics therefore clearly poses most risk," a finding that "contradicts one of the main assumptions made questioning the threat of usage of antibiotics in food animals," conclude the authors.

Sources: Mary Ann Liebert, Inc., Publisher AlphaGalileo Foundation.

Ovarian Cancer Screenings Raise Risk Of Health Problems And Do Not Reduce Mortality


Transvaginal ultrasound and the CA-125 blood test do not prevent females from dying of ovarian cancer - in fact the invasive medical procedures may be linked to health problems, researchers from the University of Alabama at Birmingham wrote in the Journal of the American Medical Association. The CA-123 blood test measures levels of a tumor marker which is more elevated in women with ovarian cancer, and some other cancers.

Edward Partridge, M.D., director of the UAB Comprehensive Cancer Center and president of the American Cancer Society Inc., said:

"The message is clear: No woman should be getting a transvaginal ultrasound and CA-125 with the belief that it is going to impact her ultimate mortality. This is not an effective strategy, and it should not be implemented."

According to the American Cancer Society, approximately 21,880 women were diagnosed with ovarian cancer in 2010, in that same year 13,850 women died of the disease.

In the majority of cases the disease is diagnosed when the cancer is well advanced. Only about 30% of newly diagnosed patients survive for at least five years.

The trial set out to determine whether early detection - ovarian cancer screening - might improve prognosis.

The investigators gathered data on mortality results from the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial involving almost 80,000 females aged from 55 to 74 years at 10 screening centers across the USA between November 1993 and July 2001.

Half the participants had transvaginal ultrasound for four years and CA-125 annual screenings for six years. The other half had routine medical care but with no screenings. All the women were monitored for 12 years up to February 2010.

The researchers found that there was no statistical difference in the survival rates in the two groups. This suggests that simultaneous transvaginal ultrasound and CA-125 have no effect in disease-specific mortality for women with average ovarian cancer risk.

Not only do the screenings apparently not reduce mortality rates, they are also associated with nausea, bruising, bleeding and fainting, the researchers revealed. Unnecessary diagnostic tests caused by false positives may lead to heart problems, bowel injury and infection. 1,080 of the women with false-positive results had their ovaries surgically removed, and 222 of them had a major surgical complication.

Partridge added:

"There is reasonable data in this study that shows that ovarian cancer-screening causes more harm than good; in fact it shows no good comes out of it.

This study shows that we need better markers that are more sensitive and specific for the disease, along with improved imaging technologies. We have scientists who are working in those areas, but more research and research funding is needed to help us better understand the beginnings of the disease, how it progresses and how we can prevent it." "

"Effect of Screening on Ovarian Cancer Mortality - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial"

Simultaneous PET/MRI Device - Siemens Biograph MMR System - Approved By FDA

A device that simultaneously performs a PET (positron emission tomography) scan and an MRI (magnetic resonance imaging) scan, called the Siemens Biograph mMR system, has been cleared by the FDA (US Food and Drug Administration).

A PET scan sees how internal parts of the body are functioning - it tracks metabolism, movement. A radioactive chemical tracer is injected into the patient's bloodstream. When inside, the tracer goes to areas inside the body that use the natural chemical. For example, fluorodeoxyglucose (FDG) is tagged to glucose to make a radiotracer. Cancers use glucose differently, so FDG can show up cancers.
An MRI machine uses radio waves and a magnetic field to create detailed images of internal parts of the body, such as soft tissues, organs and bones.

Siemens Biograph mMR system can do simultaneous imaging, it can show up increased soft tissue contrast, and uses less radiation than a PET or CT (computer tomography) scan, the FDA informs.

Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health, said:

"The Siemens PET/MRI system allows two tests to run simultaneously without having to move the patient to a different scanning system. Minimizing changes in a patient's position between tests allows physicians to compare images more easily and helps them get the most accurate information possible."

Rather than using CT to produce detailed pictures of internal parts of the body, the Siemens PET/MRI system uses MRI, which produces greater detail in virtually all the body's internal structures than a CT does. MRI images are based mainly on water concentrations in the body, while the CT uses X-rays. With this new device the health care professional will have valuable additional data about a patient's condition.
With the Biograph mMR system, the patient is exposed to much lower radiation levels compared to a PET/CT system. Patients who have to undergo several scans will benefit, as well as other sensitive populations, such as young children.

The FDA evaluated the results of bench tests that compared the Biograph mMR system with a standard PET/CT device.

Anyone who requires diagnostic PET or MRI imaging is a potential candidate for the Siemens Biograph mMR system.

The FDA added:

"However, people with pacemakers, defibrillators or other implanted electronic devices should not be scanned with the Biograph mMR system unless those devices are specifically indicated for use in the MRI environment, because the strong magnetic fields of the MRI system may interfere with those devices."

In a communique, Siemens Medical Solutions wrote:

"MR and PET have become an established part of everyday healthcare routines and have proven themselves to be valuable clinical diagnostic tools. The integration of these two technologies into a single system capable of simultaneous acquisition brings the potential to revolutionize the diagnosis of many conditions. Initial research suggests that with this system, Molecular MR can scan the entire body in as little as 30 minutes for the combined exams, compared to one hour or more for sequential MR and PET examinations."
Siemens said that if you look at it from the patient's point of view, this new device means one exam instead of two. The advantage for the medical center is that it is only one system; it takes up less space, there is just one investment, which in the longer-run will give significant economic benefits.

A Siemen's spokesperson said that this device opens new horizons with respect to finding diseases earlier. It allows for a faster understanding during follow up on how treatment is working. In the areas of neurology and oncology, and later on cardiology, it will allow for improved diagnostics.